In their clinical practice, the specialists we consulted reserve chemotherapy for the treatment of patients with triple-negative breast cancer, aggressive hormone receptor-positive disease, visceral crisis, or hormone therapy resistance. Here, NR4A1 is linked to triple-negative breast carcinoma.